Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
10/08/2012 | 07:44am CET

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
12:47p SANOFI : Dubai Science Park and Sanofi announce partnership to tackle rare disea..
08:20a 11 Key Questions Answered for Rapid, Rigorous and Reproducible Pharmaceutical..
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
07:01a SANOFI : and Lonza Enter into a Strategic Partnership to Establish a Large-Scale..
02/24 SANOFI : House Democrats demand affordable prices for taxpayer-funded Zika vacci..
02/24 REP. SCHAKOWSKY : House Democrats Demand Affordable Prices for Taxpayer-Funded Z..
02/23 INTERCEPT PHARMACEUTICALS, INC. (NAS : ICPT) Files An 8-K Results of Operations ..
02/20 SANOFI : Disclosure of trading in own shares
02/17 SANOFI : JHL Biotech Form Strategic Partnership
02/16 REGENERON PHARMACEUTICALS : Appeals Court Grants Stay of Permanent Injunction fo..
More news
Sector news : Pharmaceuticals - NEC
09:38pDJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
06:13p FTSE ends higher on some positive earnings, insurers slip
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04:15p Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially Blockb..
02:46p Buffett's 2017 Letter To Shareholders - 3 Stocks Close To His Purchase Price
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/21 PROTALIX BIOTHERAPEUTICS : New Institutional Ownership Swells Ahead Of Major Cat..
Financials (€)
Sales 2017 36 459 M
EBIT 2017 9 209 M
Net income 2017 5 892 M
Debt 2017 5 034 M
Yield 2017 3,79%
P/E ratio 2017 14,81
P/E ratio 2018 16,79
EV / Sales 2017 2,99x
EV / Sales 2018 2,86x
Capitalization 104 111 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,3 €
Spread / Average Target 2,2%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.79%109 848
JOHNSON & JOHNSON6.53%333 891
ROCHE HOLDING LTD.5.42%210 192
PFIZER INC.5.48%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.12.38%182 412
More Results